Pamela L. Kunz, MD, Yale University School of Medicine, New Haven, CT, talks on the challenging of managing endocrine tumors, including determination of treatment sequencing. Patients with low-grade or slow growing endocrine tumors tend to be treated with first-line somatostatin analogues, such as octreotide or lanreotide, with options expanding within the second-line treatment setting. Upcoming trials are utilizing comparator arms, including a Phase II trial (NCT05247905) comparing capecitabine plus temozolomide to lutetium Lu 177-dotatate in advanced pancreatic neuroendocrine tumors. Such trials enables comparison of active agents which has previously been lacking in the field. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.